HomeInsightsStock Comparison

Lupin Ltd vs Neuland Laboratories Ltd Stock Comparison

Lupin Ltd vs Neuland Laboratories Ltd Stock Comparison

Last Updated on: Dec 18, 2025

Key Highlights

  • The Latest Trading Price of Lupin Ltd is ₹ 2118 as of 18 Dec 15:30.
  • The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 yearsThe P/E Ratio of Neuland Laboratories Ltd changed from 22.5 on March 2020 to 59.9 on March 2025 . This represents a CAGR of 17.73% over 6 years.
  • The Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 92522 crore on March 2025 . This represents a CAGR of 23.00% over 6 yearsThe Market Cap of Neuland Laboratories Ltd changed from ₹ 363.66 crore on March 2020 to ₹ 15494 crore on March 2025 . This represents a CAGR of 86.89% over 6 years.
  • The revenue of Lupin Ltd for the Sep '25 is ₹ 7137 crore as compare to the Jun '25 revenue of ₹ 6347 crore. This represent the growth of 12.45% The revenue of Neuland Laboratories Ltd for the Sep '25 is ₹ 516.07 crore as compare to the Jun '25 revenue of ₹ 300.61 crore. This represent the growth of 71.67%.
  • The ebitda of Lupin Ltd for the Sep '25 is ₹ 2431 crore as compare to the Jun '25 ebitda of ₹ 1806 crore. This represent the growth of 34.6% The ebitda of Neuland Laboratories Ltd for the Sep '25 is ₹ 157.35 crore as compare to the Jun '25 ebitda of ₹ 42.34 crore. This represent the growth of 271.63%.
  • The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 1484 crore over 10 quarters. This represents a CAGR of 60.73% The net profit of Neuland Laboratories Ltd changed from ₹ 61.88 crore to ₹ 96.85 crore over 10 quarters. This represents a CAGR of 19.62% .
  • The Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 13.79 % on March 2025 . This represents a CAGR of -15.30% over 6 yearsThe Dividend Payout of Neuland Laboratories Ltd changed from 16.25 % on March 2020 to 5.97 % on March 2025 . This represents a CAGR of -15.37% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Neuland Laboratories Ltd

  • Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
  • The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin.
  • Neuland Drugs & Pharmaceuticals Pvt.
  • Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
  • NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

Lupin Ltd News Hub

News

Lupin gets EIR from US FDA for Nagpur-based injectable facility

The EIR was issued following an inspection of the facility from 08 September 2025 to 16 Se...

Read more

17 Dec 2025 10:53

News

Lupin receives SBTi validation for its climate targets

Lupin announced that its greenhouse gas (GHG) emissions reduction targets have been offici...

Read more

16 Dec 2025 10:06

News

Lupin Manufacturing Solutions partners with PolyPeptide Group AG

Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin, today announced a long-term st...

Read more

12 Dec 2025 12:14

News

Lupin receives USFDA tentative nod for Siponimod tablets

The product is a generic equivalent of Novartis Pharmaceuticals' Mayzent Tablets and is in...

Read more

05 Dec 2025 10:05

News

Lupin receives USFDA tentative approval for Siponimod Tablets

Lupin today announced that it has received tentative approval from the United States Food ...

Read more

05 Dec 2025 11:15

News

Lupin inks exclusive U.S. licensing deal with Valorum Biologics for biosimilar Armlupeg

Under the terms of the agreement, Valorum will handle the commercialization and distributi...

Read more

04 Dec 2025 14:45

Neuland Laboratories Ltd News Hub

News

Neuland Labs rises after Q2 PAT spurts 195% YoY to Rs 97 cr

On a quarter-on-quarter (QoQ) basis, the company's net profit zoomed 596.76%, while revenu...

Read more

10 Nov 2025 10:37

News

Volumes spurt at Neuland Laboratories Ltd counter

India Cements Ltd, Five-Star Business Finance Ltd, Sagility Ltd, Endurance Technologies Lt...

Read more

30 Oct 2025 11:00

News

Neuland Laboratories schedules board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 7 Nov...

Read more

25 Oct 2025 11:28

News

Neuland Laboratories to hold board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 31 Ju...

Read more

15 Jul 2025 09:52

News

Neuland Laboratories Ltd leads gainers in 'A' group

Anand Rathi Wealth Ltd, Piramal Enterprises Ltd, Vodafone Idea Ltd and Tega Industries Ltd...

Read more

14 Jul 2025 12:00

News

Volumes soar at Neuland Laboratories Ltd counter

Ola Electric Mobility Ltd, Anand Rathi Wealth Ltd, Castrol India Ltd, Piramal Enterprises ...

Read more

14 Jul 2025 14:30

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Neuland Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Neuland Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Lupin Ltd and Neuland Laboratories Ltd

Which company has a larger market capitalization, Lupin Ltd or Neuland Laboratories Ltd?

Market cap of Lupin Ltd is 96,761 Cr while Market cap of Neuland Laboratories Ltd is 20,293 Cr

What are the key factors driving the stock performance of Lupin Ltd and Neuland Laboratories Ltd?

The stock performance of Lupin Ltd and Neuland Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Neuland Laboratories Ltd?

As of December 18, 2025, the Lupin Ltd stock price is INR ₹2118.25. On the other hand, Neuland Laboratories Ltd stock price is INR ₹15817.15.

How do dividend payouts of Lupin Ltd and Neuland Laboratories Ltd compare?

To compare the dividend payouts of Lupin Ltd and Neuland Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions